Vitamin D enhances production of soluble ST2, inhibiting the action of IL-33 - 05/03/15
Doi : 10.1016/j.jaci.2014.09.044
Paul E. Pfeffer, MRCP a, Yin-Huai Chen, MSc a, Grzegorz Woszczek, PhD a, Nick C. Matthews, PhD a, Elfy Chevretton, FRCS b, Atul Gupta, MRCPH a, c, Sejal Saglani, MD c, Andrew Bush, MD c, Chris Corrigan, PhD a, David J. Cousins, PhD a, d, Catherine M. Hawrylowicz, PhD a 
a MRC and Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, Guy's Hospital, London, United Kingdom
b Department of ENT, Guy's Hospital, Great Maze Pond, London, United Kingdom
c MRC and Asthma UK Centre for Allergic Mechanisms of Asthma, Imperial College London, Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom
d Department of Infection, Immunity and Inflammation, University of Leicester, Glenfield Hospital, Leicester, United Kingdom
| P.E.P. is a Wellcome Trust Clinical Research Training Fellow, and this research was supported by the Wellcome Trust (grant 098882/Z/12/Z). This research was also supported by the National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' National Health Service (NHS) Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. A. B. was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. |
|
| Disclosure of potential conflict of interest: P. E. Pfeffer has received research support from a Wellcome Trust Clinical Research Training Fellowship. C. Corrigan has consultant arrangements with Novartis, has received research support from Novartis, has received payment for lectures from Novartis and GlaxoSmithKline, and has received travel support from Novartis and Boehringer Ingelheim. D. J. Cousins has received research support from the Medical Research Council, Asthma UK, the National Institute for Health Research, and GlaxoSmithKline. C. M. Hawrylowicz has received research support from the Wellcome Trust, was provided access to central equipment and resources by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London, has received payment for lectures from Boehringer Ingelheim, and is on the national grant review board for the Academy of Finland's evaluation panel (RCH413–Immunology & Medical Microbiology). The rest of the authors declare that they have no relevant conflicts of interest. |
© 2014
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 135 - N° 3
P. 824 - mars 2015 Retour au numéro
Article précédent
- High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma
- Stephen J. Fowler, Gaël Tavernier, Robert Niven
- Claudin-1 polymorphism modifies the effect of mold exposure on the development of atopic dermatitis and production of IgE
- Ho-Sung Yu, Mi-Jin Kang, Ji-Won Kwon, So-Yeon Lee, Eun Lee, Song-I. Yang, Young-Ho Jung, Kyungmo Hong, Young-Joon Kim, Seung-Hwa Lee, Ha-Jung Kim, Hyung Young Kim, Ju-Hee Seo, Byoung-Ju Kim, Hyo-Bin Kim, Soo-Jong Hong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?